Immunovant Stock Gross Profit

IMVT Stock

USD 26.87 0.33 1.24%

Immunovant fundamentals help investors to digest information that contributes to Immunovant's financial success or failures. It also enables traders to predict the movement of Immunovant Stock. The fundamental analysis module provides a way to measure Immunovant's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovant stock.

		Last Reported	Projected for Next Year
	Gross Profit	-231 K	-242.6 K

Gross Profit is likely to drop to about (242.6 K) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immunovant Company Gross Profit Analysis

Immunovant's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Current Immunovant Gross Profit

(242.6K)

Most of Immunovant's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunovant Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Immunovant is extremely important. It helps to project a fair market value of Immunovant Stock properly, considering its historical fundamentals such as Gross Profit. Since Immunovant's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunovant's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunovant's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Total Liab	Total Current Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		1.0	0.91	0.63	0.91	1.0	-0.94	-1.0	-0.95	0.43	0.92	-0.89	0.96	-0.71	0.94	0.96	0.2	0.94	0.91
Total Stockholder Equity	1.0		0.9	0.62	0.9	1.0	-0.94	-1.0	-0.95	0.43	0.92	-0.88	0.96	-0.71	0.94	0.96	0.2	0.94	0.9
Net Tangible Assets	0.91	0.9		0.7	0.95	0.91	-0.98	-0.92	-0.79	0.46	0.97	-0.9	0.97	-0.35	0.97	0.97	0.39	0.97	0.95
Accounts Payable	0.63	0.62	0.7		0.69	0.63	-0.62	-0.64	-0.48	0.95	0.62	-0.53	0.67	-0.22	0.61	0.67	0.09	0.61	0.67
Total Liab	0.91	0.9	0.95	0.69		0.91	-0.92	-0.92	-0.88	0.49	0.99	-0.89	0.96	-0.42	0.98	0.96	0.29	0.98	0.98
Total Current Assets	1.0	1.0	0.91	0.63	0.91		-0.94	-1.0	-0.95	0.43	0.92	-0.89	0.96	-0.71	0.94	0.96	0.2	0.94	0.91
Current Deferred Revenue	-0.94	-0.94	-0.98	-0.62	-0.92	-0.94		0.95	0.84	-0.36	-0.95	0.9	-0.96	0.45	-0.97	-0.96	-0.33	-0.97	-0.94
Net Debt	-1.0	-1.0	-0.92	-0.64	-0.92	-1.0	0.95		0.94	-0.44	-0.94	0.89	-0.97	0.68	-0.95	-0.97	-0.21	-0.95	-0.92
Retained Earnings	-0.95	-0.95	-0.79	-0.48	-0.88	-0.95	0.84	0.94		-0.31	-0.89	0.8	-0.89	0.78	-0.89	-0.89	-0.05	-0.89	-0.88
Net Receivables	0.43	0.43	0.46	0.95	0.49	0.43	-0.36	-0.44	-0.31		0.39	-0.32	0.45	-0.19	0.37	0.45	-0.05	0.37	0.45
Capital Surpluse	0.92	0.92	0.97	0.62	0.99	0.92	-0.95	-0.94	-0.89	0.39		-0.88	0.98	-0.43	0.99	0.98	0.28	0.99	0.99
Deferred Long Term Liab	-0.89	-0.88	-0.9	-0.53	-0.89	-0.89	0.9	0.89	0.8	-0.32	-0.88		-0.89	0.47	-0.94	-0.89	-0.61	-0.94	-0.83
Net Invested Capital	0.96	0.96	0.97	0.67	0.96	0.96	-0.96	-0.97	-0.89	0.45	0.98	-0.89		-0.51	0.98	1.0	0.28	0.98	0.97
Short Long Term Debt	-0.71	-0.71	-0.35	-0.22	-0.42	-0.71	0.45	0.68	0.78	-0.19	-0.43	0.47	-0.51		-0.47	-0.51	0.2	-0.47	-0.43
Capital Stock	0.94	0.94	0.97	0.61	0.98	0.94	-0.97	-0.95	-0.89	0.37	0.99	-0.94	0.98	-0.47		0.98	0.38	1.0	0.97
Net Working Capital	0.96	0.96	0.97	0.67	0.96	0.96	-0.96	-0.97	-0.89	0.45	0.98	-0.89	1.0	-0.51	0.98		0.27	0.98	0.97
Short Term Debt	0.2	0.2	0.39	0.09	0.29	0.2	-0.33	-0.21	-0.05	-0.05	0.28	-0.61	0.28	0.2	0.38	0.27		0.38	0.17
Common Stock	0.94	0.94	0.97	0.61	0.98	0.94	-0.97	-0.95	-0.89	0.37	0.99	-0.94	0.98	-0.47	1.0	0.98	0.38		0.97
Property Plant Equipment	0.91	0.9	0.95	0.67	0.98	0.91	-0.94	-0.92	-0.88	0.45	0.99	-0.83	0.97	-0.43	0.97	0.97	0.17	0.97

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Immunovant

Gross Profit Over Time

Immunovant Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.

Immunovant is currently under evaluation in gross profit category among its peers.

Immunovant ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.

Environmental

Governance

Social

Immunovant Fundamentals

	Return On Equity	-0.92
	Return On Asset	-0.55
	Current Valuation	3.42 B
	Shares Outstanding	146.78 M
	Shares Owned By Insiders	55.64 %
	Shares Owned By Institutions	54.57 %
	Number Of Shares Shorted	13.1 M
	Price To Book	8.68 X
	EBITDA	(269.98 M)
	Net Income	(259.34 M)
	Cash And Equivalents	427.2 M
	Cash Per Share	3.66 X
	Total Debt	138 K
	Debt To Equity	0 %
	Current Ratio	21.48 X
	Book Value Per Share	3.06 X
	Cash Flow From Operations	(214.23 M)
	Short Ratio	19.69 X
	Earnings Per Share	(2.21) X
	Target Price	48.93
	Number Of Employees	207
	Beta	0.71
	Market Capitalization	3.9 B
	Total Asset	666.37 M
	Retained Earnings	(825.68 M)
	Working Capital	617.16 M
	Net Asset	666.37 M

About Immunovant Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC